Back to search results

Low-Intensity Mechanical Stimulation for Blood Cancers

This study is testing low-intensity mechanical stimulation (LIMS) vibration therapy for patients with blood cancers (hematologic malignancies). Many patients with these cancers have a blood and/or bone marrow transplant (HCT) or cellular therapy. LIMS therapy delivers vibrations that may help bone growth, increase muscle strength, and activate T-cells, which are important for fighting cancer. The study aims to see if LIMS can prevent bone loss or improve T-cell development in patients undergoing or planning to undergo HCT or cellular therapies. You may be able to join if you are 18 or older and are scheduled for an HCT, or if you are a patient with Non-Hodgkin lymphoma. The study will look at how long patients use LIMS and how well CAR T-cell therapy works.

Study design
This interventional study plans to enroll 75 participants into two groups (cohorts). It is not specified if the study is randomized or blinded.
What's involved
If you are in Cohort 1, you will use a LIMS board at home for 10 minutes daily from about 8 days before your HCT until 180 days after. You will also have DEXA scans and may have blood draws. If you are in Cohort 2, you will use the LIMS board for 10 minutes twice daily for 14 days and have blood draws throughout the trial.
Compensation
Not stated in the trial record.
Follow-up
For Cohort 1, the primary endpoint is measured up to 120 days after HCT. For Cohort 2, the primary endpoint is measured up to 120 days after HCT.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05893940

Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients

Recruiting
NAAges 18+InterventionalPrevention
Roswell Park Cancer Institute
~75 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:Low Intensity Vibration TherapyDual X-ray AbsorptiometryBiospecimen Collection

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
time spent on LIMS - Cohort I
Measured over Up to 120 days post hematopoietic cell transplantation (HCT)
+1 more outcome measured

Conditions

Hematopoietic and Lymphoid System Neoplasm

Explore related trials

Chronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaFollicular LymphomaHematologic NeoplasmMantle Cell LymphomaNon-Hodgkin Lymphoma

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Megan Herr, MD · PRINCIPAL_INVESTIGATOR · Roswell Park Comprehensive Cancer Center

Who to contact

Megan Herr, MD
[email protected]
716-845-3557
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

COHORT I: Meet eligibility criteria for first autologous or allogeneic HCT (patients with preexisting osteoporosis are eligible)
COHORT I: Scheduled to undergo an autologous or allogeneic HCT
COHORT 1: \>= 18 years of age
COHORT 1: Patient must understand the investigational nature of this study and sign an institutional review board approved written informed consent form prior to receiving any study related procedure
COHORT II: Diagnosis of non-Hodgkin lymphoma (specifically diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia; patients with preexisting osteoporosis are eligible)
COHORT II: Patient must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion

Any prior allogeneic HCT
Any prior autologous HCT for those patients who have a planned auto HCT
Pre-transplant weight \>= 275 lbs. (max weight for the board)
Body mass index (BMI) \< 18 kg/m\^2
Recipient of cord blood transplant
Multiple myeloma or amyloidosis diagnosis
History of a central nervous system (CNS) hemorrhage \< 60 days
History of any aneurysm (cerebral, aortic, etc.)
A recent pulmonary embolism or deep vein thrombosis
A cardiac pacemaker
Prior history of non-traumatic (spontaneous) fracture
Total joint replacement (any joint)
History of kidney stones or gall stones within the last 2 years unless a cholecystectomy was performed
Any prosthetic lower extremity or limb
Pregnant or nursing female patients
Unwilling or unable to follow protocol requirements
Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive study intervention
Planned CAR T-cell therapy within the next 2 months
Prior CAR T-cell therapy
Active treatment within the last 60 days
Pre-transplant weight ≥ 275 lbs. (max weight for the board)
BMI \< 18 kg/m\^2
History of a CNS hemorrhage \< 60 days
History of any aneurysm (cerebral, aortic, etc.)
A recent pulmonary embolism or deep vein thrombosis
A cardiac pacemaker
Recent history (\< 60 days) of non-traumatic (spontaneous) fracture
Recent surgery (\< 60 days)
Pregnant or nursing female patients
Unwilling or unable to follow protocol requirements
Any condition which in the investigator's opinion deems the patient an unsuitable candidate to receive study intervention

What this trial measures

  • time spent on LIMS - Cohort IUp to 120 days post hematopoietic cell transplantation (HCT)

    Will assess how much time and days use throughout study period

  • Chimeric antigen receptor (CAR) T-cell product efficacy - Cohort IIup to 120 days post hematopoietic cell transplantation

    Blood samples will be collected for CAR-T cell efficacy before and after LIMS sessions